Neuphoria Therapeutics NEUP

Neuphoria Therapeutics Inc. is a clinical stage biotechnology company focused on developing therapies for neuropsychiatric disorders. The company's lead product candidate is BNC210, an oral selective negative allosteric modulator of the alpha7 nicotinic acetylcholine receptor. BNC210 is being advanced for the acute treatment of social anxiety disorder and the chronic treatment of posttraumatic stress disorder. In addition to BNC210, Neuphoria maintains a collaboration with Merck to develop alpha7 receptor positive allosteric modulators for cognitive impairment associated with Alzheimer disease and other central nervous system conditions. The company also holds a portfolio of early stage central nervous system assets and legacy oncology programs that are being pursued through partnerships.

The company generates revenue primarily through upfront payments, milestone payments, and royalties from its licensing and collaboration agreements. It has received upfront payments totaling $20 million from the Merck collaboration and an additional $10 million when the first compound from that partnership entered phase 1 clinical trials. In March 2025 Neuphoria received a $15 million milestone payment from Merck upon the initiation of a phase 2 trial evaluating MK 1167 for Alzheimer disease dementia. Under the Merck agreement the company is eligible to receive up to $450 million in further research and commercial milestone payments plus royalties on net sales of any licensed medicines. Through its agreement with Carina Biotech Neuphoria is eligible to receive up to A$118 million in development regulatory and commercial milestone payments and royalties on net sales of licensed products, with Carina having already paid A$1 million upon initiation of a phase 1 trial of its CAR T therapy. The company has not yet commercialized any products so all current revenue stems from these partnership arrangements.

Neuphoria Therapeutics Inc. positions itself as a leader in the development of novel therapies for neuropsychiatric conditions that currently lack adequate treatment options. The company's focus on social anxiety disorder and posttraumatic stress disorder addresses a combined patient population of over 27 million individuals in the United States alone. Unlike existing therapies such as selective serotonin reuptake inhibitors, serotonin and norepinephrine reuptake inhibitors, and off label benzodiazepines, BNC210 is designed to provide rapid onset of action without sedative cognitive impairing or addictive effects. The company's alpha7 receptor targeting approach is supported by preclinical data showing modulation of amygdala activity and by clinical evidence demonstrating anxiety reduction in healthy volunteer models. Neuphoria has secured Fast Track designation from the FDA for both its social anxiety disorder and posttraumatic stress disorder programs facilitating expedited review and potential early market entry. Strategic collaborations with established pharmaceutical companies such as Merck provide validation of the company's scientific platform and access to substantial financial resources and expertise. The competitive landscape includes large pharmaceutical firms with approved antidepressants and generic manufacturers but Neuphoria believes its differentiated mechanism and safety profile offer a distinct advantage.

Neuphoria Therapeutics Inc. lists Merck & Co., Inc. and Carina Biotech as its key collaboration partners and sources of current revenue. The company works with these entities to advance its alpha7 receptor programs and its oncology assets through licensing and milestone driven agreements. While no commercial product is available yet the eventual customers for any approved therapies will be patients suffering from neuropsychiatric disorders and oncology indications.